Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ABL Bio Inc. (298380.KQ)
KRW80,500.00
-1,000.00 (-1.23%)
KR KOE Healthcare Medical - Pharmaceuticals
Address
16 Daewangpangyo-Ro 712 Beon-Gil 13488
Seongnam, KR
Seongnam, KR
CEO
Sang Hoon Lee
Website
ablbio.com
IPO
2018-12-19
ISIN KR7298380007
Description
ABL Bio Inc. is a biotechnology research company based in Seongnam, South Korea. The firm is dedicated to advancing therapeutic medications, primarily concentrating its efforts on treatments for immuno-oncology and neurodegenerative conditions. Its current lineup of investigational drugs features ABL001, various cancer immunotherapies, ADCs, and ABL301.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW80,500.00
-1,000.00 (-1.23%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
517.5K
Beta
0.21
Float Shares
40.93M
Free Float %
74.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.80% | +3.17% | -17.57% | -31.29% | +2.60% | -33.50% | +117.76% | +499.08% | +604.61% | +604.61% | +604.61% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
80,500.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
35.69
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +9.5%+137.6% ★ Q1'26: +506.8% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +18.1%+39.2% ★ Q1'26: +55.2% (vs Q1'25)
-
FCF margin Medical - Pharmaceuticals: +29.9%-67.0% Q1'26: +249.1% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +4.8%-50.9% Q1'26: -131.1% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.0%-41.5% Q1'26: -137.7% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: -0.1%+12.1% Q1'26: +14.8% (vs Q1'25)
-
Debt / EBITDA Medical - Pharmaceuticals: -0.11×-1.50× Q1'26: -0.85× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
65.55B
est: 32.10M (+204,096.4%)
|
33.40B
est: 42.00B (-20.5%)
|
79.35B
est: 88.76B (-10.6%)
|
94.12B
27.00B – 138.00B
+6.0% YoY
|
114.54B
28.00B – 175.70B
+21.7% YoY
|
| EBITDA |
2.10B
est: -18.40M (+11,537.9%)
|
-53.15B
est: -19.58B (-171.4%)
|
-36.94B
est: -41.39B (+10.7%)
|
-43.89B
-64.35B – -12.59B
-6.0% YoY
|
-53.41B
-81.93B – -13.06B
-21.7% YoY
|
| EBIT |
-496.01M
est: -18.88M (-2,527.7%)
|
-55.49B
est: -20.56B (-169.9%)
|
-40.39B
est: -43.45B (+7.0%)
|
-46.08B
-67.56B – -13.22B
-6.0% YoY
|
-56.07B
-86.02B – -13.71B
-21.7% YoY
|
| Net Income |
-2.65B
est: -55.66B (+95.2%)
|
-55.53B
est: -30.43B (-82.5%)
|
-37.88B
est: -4.93B (-667.9%)
|
-6.56B
-33.93B – 11.36B
-33.0% YoY
|
11.54B
-23.59B – 45.88B
+275.9% YoY
|
| SGA |
7.94B
est: 13.96M (+56,818.5%)
|
10.08B
est: 14.57B (-30.9%)
|
14.49B
est: 30.80B (-53.0%)
|
32.66B
9.37B – 47.89B
+6.0% YoY
|
39.75B
9.72B – 60.97B
+21.7% YoY
|
| EPS |
-55.32
est: -1,159.00 (+95.2%)
|
-1,157.23
est: -565.00 (-104.8%)
|
-703.38
est: -91.60 (-667.9%)
|
-121.80
-630.00 – 211.00
-33.0% YoY
|
214.25
-438.00 – 852.00
+275.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-10 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
73.63B
OE per share TTM
1,551.18
Owner's Yield
1.02%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
107.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-395.98M
Shares Outstanding
55.13M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sang Hoon Lee | Founder, President & Chief Executive Officer | 889M | — |
| Jaecheon Lee | Executive Vice President, MD & Chief Financial Officer | 595M | male |
| Hakju Kwon | Senior Vice President, Head of Neuroscience & NCD | — | — |
| Jung Dae Kim | Executive Vice President & Chief Operating Officer | — | male |
| Sung Ju Moon | Executive Vice President & Chief ADC Development Officer | — | — |
| You Weon-Kyoo | Executive Vice President, Chief Scientific Officer & Head of R&D | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 298380.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
